Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Phase 2 Study of Preoperative Chemotherapy With Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer
Sponsor: Celgene Corporation
A PHASE2 clinical study on Pancreatic Adenocarcinoma and Resectable Pancreatic Carcinoma, this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 13 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2021 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Feb 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 8 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2018 — Apr 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jan 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Celgene Corporation
- OHSU Knight Cancer Institute
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .